Financial reports
ARS
2023 FY
Annual report to shareholders
23 Apr 24
10-K
2023 FY
Annual report
21 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
21 Apr 23
10-K
2022 FY
Annual report
16 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
Current reports
8-K
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
21 Mar 24
8-K
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
20 Mar 24
8-K
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
1 Feb 24
8-K
Results of Operations and Financial Condition
8 Jan 24
8-K
Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
9 Nov 23
8-K
Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis
6 Nov 23
8-K
Regulation FD Disclosure
2 Oct 23
8-K
Regulation FD Disclosure
5 Sep 23
8-K
Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201
22 Aug 23
8-K
Cabaletta Bio Reports Second Quarter 2023 Financial
10 Aug 23
Registration and prospectus
S-3ASR
Automatic shelf registration
21 Mar 24
S-8
Registration of securities for employees
21 Mar 24
S-8
Registration of securities for employees
10 Aug 23
424B5
Prospectus supplement for primary offering
18 May 23
424B5
Prospectus supplement for primary offering
17 May 23
S-3
Shelf registration
16 Mar 23
S-8
Registration of securities for employees
16 Mar 23
424B5
Prospectus supplement for primary offering
8 Dec 22
FWP
Free writing prospectus
8 Dec 22
S-8
Registration of securities for employees
17 Mar 22
Proxies
DEFA14A
Additional proxy soliciting materials
23 Apr 24
DEF 14A
Definitive proxy
23 Apr 24
DEFA14A
Additional proxy soliciting materials
21 Apr 23
DEF 14A
Definitive proxy
21 Apr 23
DEFA14A
Additional proxy soliciting materials
21 Apr 22
DEF 14A
Definitive proxy
21 Apr 22
DEFA14A
Additional proxy soliciting materials
21 Apr 21
DEF 14A
Definitive proxy
21 Apr 21
DEF 14A
Definitive proxy
23 Apr 20
Other
EFFECT
Notice of effectiveness
27 Apr 23
CORRESP
Correspondence with SEC
24 Apr 23
UPLOAD
Letter from SEC
22 Mar 23
EFFECT
Notice of effectiveness
19 Nov 20
CORRESP
Correspondence with SEC
16 Nov 20
UPLOAD
Letter from SEC
16 Nov 20
EFFECT
Notice of effectiveness
25 Oct 19
CERT
Certification of approval for exchange listing
24 Oct 19
CORRESP
Correspondence with SEC
22 Oct 19
CORRESP
Correspondence with SEC
22 Oct 19
Ownership
4
Michael Gerard
4 Mar 24
4
David J. Chang
4 Mar 24
4
Steven Nichtberger
4 Mar 24
4
Anup Marda
4 Mar 24
4
Arun Das
4 Mar 24
4
Gwendolyn Binder
4 Mar 24
SC 13G/A
Venrock Healthcare Capital Partners III, L.P.
14 Feb 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
ALGER ASSOCIATES INC
14 Feb 24
SC 13G/A
COMMODORE CAPITAL LP
14 Feb 24